Study of ensartinib with rifampicin or itraconazole in healthy volunteers
Treatments studied
This trial tests how a drug called ensartinib interacts with two common medications (rifampicin and itraconazole) in healthy volunteers. It helps doctors understand how to adjust doses for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy adult aged 18 or older.
- Your weight is at least 110 pounds (men) or 99 pounds (women), and your body mass index is between 19 and 26.
- You have no major health problems like heart, liver, kidney, or lung disease.
- You have not taken any prescription or over-the-counter drugs, supplements, or herbal products in the last 14 days.
- You do not smoke, drink heavily, or use recreational drugs.
- You are willing to use effective birth control during the study and for 3 months after, if you are able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if a new drug (AZD4144) works differently when taken with an antifungal medicine (itraconazole) in healthy volunteers. It helps doctors understand how to adjust doses for people who need both medicines.
This study tests how a new drug called TQB3616 interacts with other medicines. It is for healthy volunteers aged 18 to 45 to help understand how the drug is processed in the body.
This study checks if itraconazole changes how the body processes HSK31858. Healthy volunteers are needed to help understand the safety and drug levels.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
This trial tests the drug ensartinib in people with advanced solid tumors (not lung cancer) that have an ALK or MET gene change. It may be an option if standard treatments are not working, not tolerated, or refused.
This trial tests whether the drug ensartinib can help prevent cancer from returning after standard chemoradiation in people with stage III ALK-mutated non-small cell lung cancer that cannot be removed by surgery. Enrolling those who have completed chemoradiation within the past 6 weeks without their cancer getting worse.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.